SHILPA MEDICARE share price has plunged 4% and is presently trading at Rs 564.0.
Meanwhile, the BSE HEALTHCARE index is at 36,831.0 (up 0.4%).
Among the top losers in the BSE HEALTHCARE index today are POLY MEDICURE (down 3.6%) and HIKAL CHEMIC (down 3.1%).
CAPLIN POINT (up 7.3%) and SUVEN PHARMACEUTICALS (up 6.5%) are among the top gainers today.
Over the last one year, SHILPA MEDICARE has moved up from Rs 254.0 to Rs 564.0, registering a gain of Rs 310.0 (up 122.1%).
On the other hand, the BSE HEALTHCARE index has moved up from 25,266.1 to 36,831.0, registering a gain of 45.8% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Cadila Healthcare (up 88.9%), Glenmark Pharma (up 88.9%) and GSK Pharma (up 87.4%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 79,245.0 (up 0.7%).
The top gainers among the BSE Sensex today are Ultratech Cement (up 5.3%) and NTPC (up 3.3%). The most traded stocks in the BSE Sensex are Tata Steel and Infosys.
In the meantime, NSE Nifty is at 24,036.1 (up 0.7%). Ultratech Cement and LTIMINDTREE are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 62,970.0 to 79,245.0, registering a gain of 16,275.0 points (up 25.8%).
SHILPA MEDICARE net profit grew 459.7% YoY to Rs 246 million for the quarter ended March 2024, compared to a loss of Rs 69 million a year ago. Net sales rose 10.7% to Rs 2,917 million during the period as against Rs 2,636 million in January-March 2023.
For the year ended March 2023, SHILPA MEDICARE reported 151.0% decrease in net profit to Rs -309 million compared to net profit of Rs 606 million during FY22. Revenue of the company fell 8.3% to Rs 10,501 million during FY23.
The current Price to earnings ratio of SHILPA MEDICARE, based on rolling 12 month earnings, stands at 150.1.
Equitymaster requests your view! Post a comment on "SHILPA MEDICARE Plunges 4%; BSE HEALTHCARE Index Up 0.4%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!